摘要
目的观察粒细胞集落刺激因子(G-CSF)联合聚乙二醇干扰素(PEG-IFNα)及利巴韦林的标准化方案与PEG-IFNα减量治疗对代偿期丙肝肝硬化抗病毒的疗效比较。方法选择代偿期丙肝肝硬化患者48例,随机分为G-CSF联合PEG-IFNα及利巴韦林标准治疗组和PEG-IFNα减量组;以慢性丙肝接受标准化抗病毒治疗方案患者28例为对照组。观察快速病毒学应答(RVR)、早期病毒学应答(EVR)、治疗结束时病毒学应答(ETVR)、持续病毒学应答(SVR)、停药后复发,并随访48周,同时观察肝功能复常和其他不良反应。组间比较采用方差分析或卡方检验分析。结果 G-CSF治疗组的ETVR率、SVR率等指标与CHC的标准化抗病毒治疗组比较,差异无统计学意义(P>0.05);但是PEG-IFN减量组在ETVR率、SVR率方面均低于CHC的标准化抗病毒治疗组,且差异有统计学意义(χ2=8.266、4.467,P均<0.05)。另外,G-CSF治疗组的ETVR率明显高于PEG-IFN减量组,且差异有统计学意义(χ2=4.009,P<0.05)。结论用GM-CSF陪伴标准化治疗方案抗病毒治疗对丙肝肝硬化患者疗效明显优于PEG-IFNα减量组。
Objective To investigate the effects of the granulocyte colony stimulating factor（G-CSF） with pegylated interferon alpha（PEG-IFNα） plus ribavirin（RBV） and PEG-IFNα reduction in the treatment of the compensatory hepatitis C virus（HCV）-related cirrhosis.Methods Fourty-eight patients with compensatory HCV-related liver cirrhosis were devided into two groups： G-CSF with PEG-IFNα plus RBV and PEG-IFNα reduction.Another 28 patients who received standardized anti-virus therapy were taken as the control group.The rapid viral response（RVR）,early virologic response（EVR）,end-treatment virologic response（ETVR）,sustained viral response（SVR） and recurrence after withdrawal were observed in the following 48 weeks.In addition,the recovery of liver function adverse reactions were recorded.Intergroup differences were assessed by ANOVA or Chi-squared test.Results The rates of ETVR and SVR in GM-CSF with PEG-IFNα plus ribavirin group between standardized anti-virus therapy group was not statistically significant（P0.05）.But the rates of ETVR and SVR in PEG-IFNα reduction group were lower than standardized anti-virus therapy group,and the difference was statistically significant（χ2=8.266、4.467,P0.05）.The rates of ETVR and SVR in GM-CSF with PEG-IFNα plus ribavirin group were higher than PEG-IFNα reduction group,but lower than the latter in the rate of recurrence.The difference was statistically significant（χ2=4.009,P0.05）.Conclusion G-CSF with PEG-IFNα plus RBV was better than PEG-IFNα reduction in the treatment of compensated HCV-related liver cirrhosis.
出处
《临床肝胆病杂志》
CAS
2013年第5期348-351,共4页
Journal of Clinical Hepatology
基金
国家自然科学基金项目(81170389)
